Technical Analysis for BWAY - Brainsway Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical BWAY trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 2.24% | |
20 DMA Resistance | Bearish | 6.90% | |
Wide Bands | Range Expansion | 6.90% | |
Fell Below 20 DMA | Bearish | 4.58% | |
Wide Bands | Range Expansion | 4.58% | |
Crossed Above 20 DMA | Bullish | -1.51% | |
Volume Surge | Other | -1.51% | |
Wide Bands | Range Expansion | -1.51% | |
Fell Below 20 DMA | Bearish | 4.46% | |
MACD Bearish Signal Line Cross | Bearish | 4.46% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Rose Above Previous Day's High | 31 minutes ago | |
Up 2% | 31 minutes ago | |
Up 1% | 31 minutes ago | |
20 DMA Support | about 1 hour ago | |
60 Minute Opening Range Breakout | about 1 hour ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/18/2020
Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience Mental Health Opioid FDA Multiple Sclerosis Stroke Psychiatry Depressive Disorder Major Depressive Disorder Smoking Neuromodulation Neurotechnology Smoking Cessation Neurophysiology Treatment Of Major Depressive Disorder Fatigue Obsessive Compulsive Disorder Addiction Neuromodulation Products Neuropsychology Post Traumatic Stress Disorder Treatment Of Depression
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience Mental Health Opioid FDA Multiple Sclerosis Stroke Psychiatry Depressive Disorder Major Depressive Disorder Smoking Neuromodulation Neurotechnology Smoking Cessation Neurophysiology Treatment Of Major Depressive Disorder Fatigue Obsessive Compulsive Disorder Addiction Neuromodulation Products Neuropsychology Post Traumatic Stress Disorder Treatment Of Depression
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.0 |
52 Week Low | 5.1 |
Average Volume | 74,498 |
200-Day Moving Average | 6.83 |
50-Day Moving Average | 8.14 |
20-Day Moving Average | 8.90 |
10-Day Moving Average | 9.28 |
Average True Range | 0.64 |
ADX | 30.26 |
+DI | 29.53 |
-DI | 21.77 |
Chandelier Exit (Long, 3 ATRs ) | 8.56 |
Chandelier Exit (Short, 3 ATRs ) | 9.65 |
Upper Bollinger Band | 10.16 |
Lower Bollinger Band | 7.64 |
Percent B (%b) | 0.52 |
BandWidth | 28.37 |
MACD Line | 0.23 |
MACD Signal Line | 0.35 |
MACD Histogram | -0.1129 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.57 | ||||
Resistance 3 (R3) | 9.53 | 9.27 | 9.47 | ||
Resistance 2 (R2) | 9.27 | 9.11 | 9.30 | 9.43 | |
Resistance 1 (R1) | 9.11 | 9.01 | 9.19 | 9.15 | 9.39 |
Pivot Point | 8.85 | 8.85 | 8.90 | 8.88 | 8.85 |
Support 1 (S1) | 8.69 | 8.69 | 8.77 | 8.73 | 8.49 |
Support 2 (S2) | 8.43 | 8.59 | 8.46 | 8.45 | |
Support 3 (S3) | 8.27 | 8.43 | 8.42 | ||
Support 4 (S4) | 8.31 |